Dual chamber injection development (Mark II). Final report, 12 April 1984-15 December 1985

Technical Report · Sat Mar 15 00:00:00 EST 1986

OSTI ID:6909344

Monroe, N; Dietrich, W C

This report describes final development, submission of NDA, and mass production of Antidote Kit, Nerve Agent, Mark II. It discusses engineering, production, quality control, materials management, and regulatory - clinical efforts. It also includes results of animal and clinical studies and study protocols. A summary of the Technical Data Package and Training Course is presented.

• Research Organization: Survival Technology, Inc., Bethesda, MD (USA)
• OSTI ID: 6909344
• Report Number(s): AD-A-192253/3/XAB; STI-21/21
• Country of Publication: United States
• Language: English

Related Subjects

37 INORGANIC
ORGANIC
PHYSICAL AND ANALYTICAL CHEMISTRY
CHEMICAL WARFARE
TRAINING
ATROPINE
INJECTION
MANAGEMENT
MASS
MATERIALS
PRODUCTION
PROGRESS REPORT
QUALITY CONTROL
ALKALOIDS
AUTONOMIC NERVOUS SYSTEM AGENTS
CONTROL
DOCUMENT TYPES
DRUGS
INTAKE
ORGANIC COMPOUNDS
PARASYMPATHOLYTICS
WARFARE
400201* - Chemical & Physicochemical Properties